Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 30, 2022.
Approximately a quarter of RAPID3 assessments, confirmed with 92% accuracy by DAS28 scores, reported patients had low disease activity and could, therefore, postpone routine clinical visits.
“Understanding the extent of the co-occurrence and identifying factors associated with an increased susceptibility could be relevant to implement case-finding strategies in specific at-risk populations," investigators stated.
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.
Manuel Francisco Ugarte-Gil, MD, MSc, explains the impact that severe flares have on health-related quality of life for patients with systemic lupus erythematosus.
Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.